Publications by authors named "Paul Matte"

Claim this Profile
H
Hydration practices during cisplatin administration: a national multicenter survey.
Paul Matte, Arnaud Saillant, Pauline Corbaux, Elise Dominjon, Adrien Rousseau

Support Care Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Towards a more "sustainable" oncology in the era of global warming?].
Anthony Turpin, Paul Matte, Matthieu Delaye, Max Piffoux

Bull Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of cancer treatments in hemodialysis patients.
Paul Matte, Kevin Bihan, Corinne Isnard-Bagnis, Noël Zahr, Antoine Thiery-Vuillemin

Bull Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Immune-checkpoint inhibitors : from love at first sight to heartbreak].
Romain Batton, Paul Matte, Michael Aoun, Auréline Lefèvre, Pierre-Emmanuel Joubert

Med Sci (Paris)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
Paul Matte, Matthieu Delaye, Alice Mc Govern, Pascal Rouby, Santiago Ponce

Gen Hosp Psychiatry· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind.
Paul Matte, Michel Ducreux

Case Rep Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Drug approval: Cabozantinib monotherapy in advanced thyroid cancers refractory or not eligible for radioactive iodine treatment, after progression under previous systemic therapies].
Paul Matte, Julien Hadoux

Bull Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Drug approval: Enfortumab vedotin-advanced urothelial carcinoma (which have previously received platinum-containing chemotherapy and immunotherapy)].
Paul Matte, Luca Campedel

Bull Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis